Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Impedimed Limited ( (AU:IPD) ) has provided an announcement.
ImpediMed Limited has received a $1.2 million R&D tax incentive refund for its research and development activities, which bolsters its cash position and supports the ongoing development and commercialization of its SOZO platform. The company’s cash balance at the end of Q2 FY26 was $23.0 million, indicating a strong financial position that aids its growth in the digital health market, particularly in cancer-related lymphoedema.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is a medical technology company based in Australia with operations in the US and Europe. It specializes in bioimpedance spectroscopy (BIS) technology to generate data for maximizing patient health. The company produces the SOZO Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for conditions such as lymphoedema, heart failure, and protein calorie malnutrition, and is sold in select global markets.
YTD Price Performance: -30.77%
Average Trading Volume: 1,724,927
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$73.35M
See more insights into IPD stock on TipRanks’ Stock Analysis page.